ALX Oncology's (ALXO) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of ALX Oncology (NASDAQ:ALXO - Free Report) in a research note released on Tuesday morning,Benzinga reports.

A number of other equities analysts have also recently issued reports on the stock. UBS Group dropped their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a "buy" rating for the company in a research note on Friday, August 16th. HC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of ALX Oncology in a research report on Tuesday, August 13th. Stifel Nicolaus reiterated a "hold" rating and set a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Finally, Lifesci Capital lowered shares of ALX Oncology from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, ALX Oncology has a consensus rating of "Moderate Buy" and an average price target of $12.50.

ALX Oncology Trading Down 9.5 %

Shares of ALXO traded down $0.14 during mid-day trading on Tuesday, reaching $1.34. The company had a trading volume of 983,163 shares, compared to its average volume of 775,974. The stock has a market cap of $70.58 million, a price-to-earnings ratio of -0.50 and a beta of 1.03. The firm has a fifty day simple moving average of $1.75 and a 200-day simple moving average of $5.85. ALX Oncology has a fifty-two week low of $1.34 and a fifty-two week high of $17.83. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALXO. Redmile Group LLC lifted its holdings in shares of ALX Oncology by 18.2% during the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company's stock worth $48,241,000 after acquiring an additional 667,245 shares during the last quarter. Marshall Wace LLP increased its stake in ALX Oncology by 423.0% in the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company's stock valued at $3,833,000 after buying an additional 514,133 shares during the period. Privium Fund Management B.V. bought a new position in ALX Oncology during the second quarter worth $2,271,000. Point72 Asset Management L.P. bought a new position in ALX Oncology in the 2nd quarter worth approximately $1,834,000. Finally, Los Angeles Capital Management LLC bought a new position in ALX Oncology in the 3rd quarter worth approximately $469,000. Institutional investors and hedge funds own 97.97% of the company's stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.